Insider Selling: Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Insider Sells 4,618 Shares of Stock

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) insider Neil Gallagher sold 4,618 shares of the stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $71,579.00. Following the completion of the transaction, the insider now directly owns 85,095 shares of the company’s stock, valued at $1,318,972.50. This represents a 5.15 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Syndax Pharmaceuticals Stock Performance

Shares of SNDX stock traded down $0.15 on Wednesday, reaching $14.86. The stock had a trading volume of 3,212,288 shares, compared to its average volume of 2,342,525. The stock has a market cap of $1.27 billion, a P/E ratio of -4.09 and a beta of 0.90. Syndax Pharmaceuticals, Inc. has a 1 year low of $12.06 and a 1 year high of $25.34. The company has a 50 day simple moving average of $14.00 and a 200 day simple moving average of $17.27.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on SNDX shares. JPMorgan Chase & Co. increased their target price on Syndax Pharmaceuticals from $33.00 to $38.00 and gave the stock an “overweight” rating in a research report on Thursday, November 21st. Citigroup raised their price objective on Syndax Pharmaceuticals from $37.00 to $45.00 and gave the company a “buy” rating in a research report on Tuesday, November 19th. StockNews.com lowered Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, November 23rd. UBS Group began coverage on Syndax Pharmaceuticals in a research report on Thursday, October 24th. They set a “buy” rating and a $37.00 price objective for the company. Finally, Scotiabank cut their target price on Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating on the stock in a research note on Wednesday, January 8th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and nine have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $36.20.

Hedge Funds Weigh In On Syndax Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. lifted its position in Syndax Pharmaceuticals by 21.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,078 shares of the company’s stock valued at $58,000 after purchasing an additional 541 shares in the last quarter. Values First Advisors Inc. purchased a new position in Syndax Pharmaceuticals during the third quarter valued at $30,000. E Fund Management Co. Ltd. lifted its position in Syndax Pharmaceuticals by 14.4% during the fourth quarter. E Fund Management Co. Ltd. now owns 12,603 shares of the company’s stock valued at $167,000 after purchasing an additional 1,583 shares in the last quarter. China Universal Asset Management Co. Ltd. lifted its position in Syndax Pharmaceuticals by 10.6% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 18,099 shares of the company’s stock valued at $239,000 after purchasing an additional 1,732 shares in the last quarter. Finally, R Squared Ltd purchased a new position in Syndax Pharmaceuticals during the fourth quarter valued at $26,000.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).